Foghorn Therapeutics Inc.
FHTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FHTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FHTX
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary Gene Traffic Control platform to develop novel therapeutics targeting the chromatin regulatory system in oncology.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Foghorn Therapeutics Inc..
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary Gene Traffic Control platform to develop novel therapeutics targeting the chromatin regulatory system in oncology.
- Proprietary Gene Traffic Control platform provides an integrated understanding of the chromatin regulatory system for target identification and drug development [sec_mda · as of 2026-03-11].
- Cash and equivalents of $70.1M as of 2026-06-30, with total revenue of $16.1M and a net loss of $7.2M for the same period [sec].
- Lead clinical candidate FHD-909 is in a Phase 1 trial partnered with Lilly, with ongoing preclinical activities for additional programs [sec_mda · as of 2026-08-06].
- Company has incurred significant operating losses since inception and expects expenses to increase as it advances its pipeline [sec_mda · as of 2026-08-06].
What works
- The Gene Traffic Control platform offers a mechanistic approach to drugging challenging oncology targets such as SMARCA2, CBP, EP300, and ARID1B [sec_mda · as of 2026-03-11].
- Partnership with Lilly for FHD-909 provides external validation and potential for shared development costs [sec_mda · as of 2026-08-06].
- Pipeline includes more than seven programs, indicating a broad research base beyond the lead candidate [sec_mda · as of 2026-03-11].
What to weigh
- Accumulated deficit and history of operating losses; shareholders' equity is negative (-$76.7M as of 2026-06-30) [sec].
- Cash runway is limited; the company expects to need substantial additional funding to support ongoing and future clinical activities [sec_mda · as of 2026-08-06].
- No approved products or product revenue; reliance on successful clinical development and regulatory approval for future revenue generation [sec_mda · as of 2026-03-11].
From the filings
Quoted directly from source documents.
The company's platform provides an integrated understanding of the chromatin regulatory system.
“Our proprietary Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact”
SEC MD&A · March 11, 2026
The company expects expenses to increase as it advances clinical activities.
“We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue to fund on-going and potential future clinical activities, including the Phase 1 clinical trial of FHD-909 partnered with Lilly”
SEC MD&A · August 6, 2026
The company has incurred significant operating losses since inception.
“Since our inception in October 2015, we have incurred significant operating losses.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2021-06-14 · Phase 1 Start for FHD-909 — A Phase 1, multicenter, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of FHD-909.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $70.1M as of 2026-06-30 may not be sufficient to fund all planned activities without additional financing [sec].
- Negative shareholders' equity — Shareholders' equity of -$76.7M as of 2026-06-30 indicates accumulated losses exceed assets [sec].
- Dependence on clinical success — No approved products; revenue depends on successful development and regulatory approval of pipeline candidates [sec_mda · as of 2026-03-11].
- Reliance on partnership — FHD-909 partnered with Lilly; any changes in partnership could impact development timelines [sec_mda · as of 2026-08-06].
What to watch
- Progress and data from the Phase 1 trial of FHD-909 partnered with Lilly [sec_mda · as of 2026-08-06].
- Updates on preclinical advancement and potential new clinical trial initiations for pipeline programs [sec_mda · as of 2026-08-06].
- Future financing activities, including potential equity offerings or partnerships, to extend cash runway [sec_mda · as of 2026-08-06].
Sources: Catalysts · SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run Foghorn Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Foghorn Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
16.8 months
OCF -$18M · Net income -$7M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
104
Total value held
$216.8M
| Holder | Shares | Value |
|---|---|---|
| flagship pioneering, llc | 12,674,120 | $60.6M |
| fmr llc | 6,047,198 | $28.9M |
| bvf inc/il | 5,842,000 | $27.9M |
| deerfield management company, l.p. | 4,394,367 | $21.0M |
| vanguard capital management llc | 2,990,178 | $14.3M |
| raymond james financial inc | 2,602,382 | $12.4M |
| blackrock, inc. | 2,364,866 | $11.3M |
| euclidean capital llc | 1,573,761 | $7.5M |
| geode capital management, llc | 848,172 | $4.1M |
| state street corp | 679,787 | $3.2M |
Showing top 10 of 104 institutional holders of Foghorn Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 3.5%
- Days to cover
- 8.4
- Shares short
- 1,376,282
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FHTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Foghorn Therapeutics Inc.?
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary Gene Traffic Control platform to develop novel therapeutics targeting the chromatin regulatory system in oncology.
What is Foghorn Therapeutics Inc.'s lead drug candidate?
Foghorn Therapeutics Inc.'s most advanced tracked candidate is fhd-909 (Phase 1) for SMARCA4 mutated cancers, with NSCLC as the primary patient population.
Who is the CEO of Foghorn Therapeutics Inc.?
Mr. Adrian H. B. Gottschalk is the chief executive officer of Foghorn Therapeutics Inc. (FHTX).
Where is Foghorn Therapeutics Inc. headquartered?
Foghorn Therapeutics Inc. (FHTX) is headquartered in Watertown, MA, United States.
What therapeutic areas does Foghorn Therapeutics Inc. focus on?
Foghorn Therapeutics Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.